News

Deal Announcements

Fate Therapeutics Nets Venture Capital Debt

Wednesday, August 14, 2013 5:53:00 AM PDT | VentureDeal
   San Diego, California  --  Biotechnology company Fate Therapeutics has received $20 million in new venture capital debt investment, according to an SEC regulatory filing.

Fate is developing a platform that focuses on regenerative and reprogramming medicine that utilizes treatments to awaken adult stem cells.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

The company is backed by a large syndicate of venture capital firm investors.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1